Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program
Retrieved on:
Monday, November 18, 2019
(AVX Pharma or AVX), a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.
Key Points:
- (AVX Pharma or AVX), a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.
- AVX completed a Phase 2a study in dry eye subjects earlier this year with its lead product candidate, AVX-012.
- By stimulating these processes in a physiological manner, TRPM8 agonists have the potential to restore tear film stability and reduce discomfort in patients with dry eye.
- This acquisition bolsters our pipeline with a clinical-stage dry eye product candidate, and we are excited to expand our footprint in ophthalmology.